The Herman Trend Alert
January 16, 2019
Tackling Depression with Digital Therapeutics
According to the World Health Organization (WHO), depression affects over 300 million people a year and results in 800,000 deaths from suicide per year. That's a lot of people who didn't have to die---if they had had the right treatment. The popular treatments for this condition are cognitive behavioral therapy, interpersonal therapy, and antidepressant medications.
Enter Otsuka America with a digital solution
The Japanese pharma company Otsuka is a leader in digital medicine for psychiatry. Teaming up with Click Therapeutics, makers of software as a prescription medical treatment, Otsuka America, a US subsidiary of the company, announced that it will create a new digital therapeutic treatment for Major Depressive Disorder (MDD). The company intends to invest more than $300 million USD in an FDA-cleared software app that will apply cognitive therapy principals either with or without prescription drugs.
Cognitive Therapy really works!
Cognitive therapy "provides a mental tool kit that can be used to challenge the negative thoughts of depression". Interestingly, studies have shown that cognitive therapy works at least as well as antidepressant pharmaceuticals in helping people with mild to moderate depression. It challenges the continuous stream of negative self-talk with realistic thinking. "With cognitive therapy, a person learns to recognize and correct negative automatic thoughts." Over time, the depressed person is able to recognize and shift away from deeply held negative beliefs that support the feelings of depression.
Seeking approval as a medical device
Like many other digital therapeutics coming to the market, the companies plan to go through the FDA process and be classified as a Software as a Medical Device. When the product hits commercial milestones, the digital health company will be getting $272 million USD from the pharma company, plus royalties.
One of many new therapeutic apps in the pipeline
Digital therapeutics have become increasingly popular with digital health and pharma companies alike. This new app comes on the heels of other successes from Sanofi and Sandoz. Last November, the FDA cleared the first software-only therapeutic: reSET, a substance use disorder, treatment, now commercially available for clinicians to prescribe to their patients. Shortly thereafter, the FDA cleared reSET-O, a digital therapeutic to treat opioid use disorder (OUD). This product was jointly developed by Pear Therapeutics and Sandoz, a division of Novartis. Moreover, in partnership with the University of Virginia, Pear is in developing a digital therapeutic for insomnia and depression. The Otsuka America product follows in the footsteps of these other digital therapeutics and reflects that this new genre holds great potential for the future.
Special thanks to mobihealthnews.com. To read the original article, click here.
© Copyright 1998-
by The Herman Group, Inc. -- reproduction for publication is encouraged, with the following attribution: From "The Herman Trend Alert," by Joyce Gioia, Strategic Business Futurist. 336-210-3548 or https://hermangroup.com. To sign up, visit https://HermanTrendAlert.com. The Herman Trend Alert is a trademark of The Herman Group, Inc."
HAPPY ANNIVERSARY TO US!
This week marks the 21st Anniversary of The Herman Trend Alert. We sincerely appreciate your loyalty. We will do our best to continue to earn that loyalty by bringing interesting, thought-provoking news articles to your email box every week.
GIVE YOUR SON OR DAUGHTER THE LEARNING EXPERIENCE OF A LIFETIME
Beginning in September, the Semester at Sea® Fall 2019 Voyage will be visiting 12 cities in 11 countries. In partnership with Colorado State University, Semester at Sea® provides students unique opportunities to interact with their professors and enjoy cultural experiences way beyond typical cruise shore excursions; the in-country field classes and programs will feature person-to-person interactions with nationals. Students earn 12-15 valuable college credits, while they visit 4 continents. Our author Joyce Gioia will be teaching Leadership and Innovation. Lifelong Learners are also welcomed on each voyage. For more information, visit Fall 2019 Voyage for Semester at Sea.
IS YOUR EMPLOYER AN EMPLOYER OF CHOICE®?
We've seen a strong resurgence in interest by employers in being recognized as an Employer of Choice®. Celebrate your employee-centered corporate culture! This coveted award is well worth the effort, yet is not easy to achieve. Download the extensive application at http://www.EmployerOfChoice.com; or for a Word® version, drop a note to Joyce@EmployerOfChoice.com or call Joyce at 336.210.3548.
OUR VERSATILE TRANSLATOR ROCKS
Excellent translation services from English, French, or German into Spanish. Especially well-versed in medicine/pharma and automobile industries. 5-year Bachelor Degree in Translation. Also editing and proofreading of all kinds of Spanish language documents. Flexible rates, depending on number of words, degree of difficulty/technicality, and turnaround. For an instant quote email Mariana Campora Lesti at firstname.lastname@example.org or contact her on SKYPE at marianacampora.
To read this Herman Trend Alert on the web: https://hermangroup.com/alert/archive_2-20-2019.html.
Herman Trend Alerts are produced by the Herman Group, strategic business futurists, Certified Management Consultants, authors, and professional speakers.
New subscribers are always welcome. There is no charge for this public service. The Herman Trend Alert is read by over 30,000 people in 90 countries, including other websites and printed periodicals. Click here to sign up for the Herman Trend Alert.
Do you enjoy receiving this weekly e-mail update? Contact us about our co-branded Herman Trend Alert service.
Subscribe or Unsubscribe to weekly Herman Trend Alert
View this week's Herman Trend Alert
Archived Weekly Herman Trend Alerts